UroToday1d
ASCO GU 2025: Treatment Patterns in Prostate Cancer Patients Who Received Darolutamide in the ARAMIS Trial in Spain: PARASEC Study
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Javier Puente discussing the PARASEC study assessing treatment patterns in prostate cancer ...
UroToday1d
ASCO GU 2025: Real-World Comparison of Cabazitaxel vs. 177-Lutetium-PSMA Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session ...
UroToday1d
ASCO GU 2025: Optyx Study: Clinical Characteristics and Preferences for Initiating Relugolix in a Cohort of US Patients in Real-World Care Settings
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Poster Session ...